4//SEC Filing
Schwab Andrew J. 4
Accession 0001415889-25-022808
CIK 0001516551other
Filed
Aug 21, 8:00 PM ET
Accepted
Aug 22, 7:07 PM ET
Size
13.0 KB
Accession
0001415889-25-022808
Insider Transaction Report
Form 4
Schwab Andrew J.
Director
Transactions
- Sale
Common Stock
2025-08-21$3.57/sh−58,642$209,352→ 1,621,043 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−6,470$22,127→ 57,493 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−2,314$8,261→ 63,963 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−163,979$560,808→ 1,457,064 total(indirect: By 5AM Ventures II, L.P.)
Holdings
- 8,167,206(indirect: By 5AM Ventures VII, L.P.)
Common Stock
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F3]The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Documents
Issuer
Skye Bioscience, Inc.
CIK 0001516551
Entity typeother
Related Parties
1- filerCIK 0001598549
Filing Metadata
- Form type
- 4
- Filed
- Aug 21, 8:00 PM ET
- Accepted
- Aug 22, 7:07 PM ET
- Size
- 13.0 KB